Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants.
Michael R HodgesSjoerd van MarleWilliam G KramerEric OpleMargaret TawadrousAbhijeet JakatePublished in: Antimicrobial agents and chemotherapy (2024)
This study is registered with ClinicalTrials.gov as NCT04166669 and with EudraCT as number 2019-003586-17.
Keyphrases